(Q36691665)

15 August 2017

1 reference

title

XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent (English)

1 reference

15 August 2017

Marcel A M Beijk

1

1 reference

15 August 2017

Jan J Piek

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Expert Review of Medical Devices

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

11-21

1 reference

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Stent coatings and local drug delivery; state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Oral everolimus inhibits in-stent neointimal growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Paclitaxel-induced cell death: where the cell cycle and apoptosis come together

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Experimental efficacy of an everolimus eluting cobalt chromium stent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Clinical experiences using everolimus-eluting stents in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Sirolimus-eluting versus uncoated stents in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Isolation of putative progenitor endothelial cells for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

Drug-eluting stents: caution and concerns for long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.1.11

21 January 2018

Identifiers

DOI

10.1586/17434440.4.1.11

1 reference

15 August 2017

1 reference